يعرض 1 - 10 نتائج من 16 نتيجة بحث عن '"Randeep Sangha"', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1
    First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    المؤلفون: A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, Luis Paz-Ares, Yuichiro Ohe, Hossein Borghaei, Kenneth J. O'Byrne, L. Lupinacci, Phuong Tran, Jong Seok Lee, Makoto Nishio, Kynan Feeney, Masayuki Takeda, Enric Carcereny, Adam Pluzanski, F. E. Nathan, Carlos Gallardo, Judith Bushong, Keunchil Park, B. Zurawski, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Gregory A. Otterson

    المساهمون: Bristol-Myers Squibb, Ono Pharmaceutical

    المصدر: Journal of Thoracic Oncology
    r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
    instname

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Adult, medicine.medical_specialty, Lung Neoplasms, Immunotherapy, First line, medicine.medical_treatment, Ipilimumab, PD-1 checkpoint inhibitor, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Chemotherapy, CTLA-4, First-line, business.industry, Confidence interval, Discontinuation, Nivolumab, Metastatic non–small cell lung cancer, Open label, Neoplasm Recurrence, Local, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f7125153a7a538998a341b2f60e83eTest
    http://hdl.handle.net/10261/305831Test


    أضف إلى المفضلة
  2. 2
    A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

    المؤلفون: Florence Atrafi, Young Kwang Chae, Martijn P. Lolkema, Philip Komarnitsky, Lauren Averett Byers, Lei He, Tian Tian, Santiago Viteri, Beibei Hu, Silpa Nuthalapati, Randeep Sangha, Antonio Calles, Nashat Y. Gabrail, Elena Garralda, Harry J.M. Groen, Elizabeth Hoening, D. Ross Camidge

    المساهمون: Medical Oncology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

    المصدر: Clinical Cancer Research, 25(2), 496-505. American Association for Cancer Research Inc.
    Clinical Cancer Research, 25(2), 496-505. AMER ASSOC CANCER RESEARCH

    مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_treatment, ABT-888, SINGLE-AGENT, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Etoposide, PLUS CARBOPLATIN, Middle Aged, CHEMOTHERAPY, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, DNA-REPAIR, Female, TRIAL, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Veliparib, Neutropenia, GERMLINE BRCA1, OVARIAN-CANCER, 03 medical and health sciences, Pharmacokinetics, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, Adverse effect, PARP INHIBITOR VELIPARIB, COMBINATION, Aged, Neoplasm Staging, Chemotherapy, business.industry, medicine.disease, Small Cell Lung Carcinoma, 030104 developmental biology, chemistry, Benzimidazoles, business

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef576ddb32ba6e108376031f782f4658Test
    https://doi.org/10.1158/1078-0432.Ccr-18-2014Test


    أضف إلى المفضلة
  3. 3
    Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors

    المؤلفون: A. Gibson, Adrian Box, Desiree Hao, A. Elegbede, Randeep Sangha, D. Gwyn Bebb, Michelle Dean

    المصدر: JTO Clinical and Research Reports
    JTO Clinical and Research Reports, Vol 2, Iss 4, Pp 100157-(2021)

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Alectinib, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Population, Context (language use), Tyrosine-kinase inhibitor, Targeted therapy, hemic and lymphatic diseases, Internal medicine, medicine, Real-world outcomes, education, Lung cancer, Survival rate, RC254-282, ALK-rearranged NSCLC, education.field_of_study, Crizotinib, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, respiratory tract diseases, Adverse events, Original Article, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597578feb01c88c7768b72930b6b88caTest
    https://doi.org/10.1016/j.jtocrr.2021.100157Test


    أضف إلى المفضلة
  4. 4
    Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective

    المؤلفون: Randeep Sangha, Brandon S. Sheffield, Rosalyn A. Juergens, Diana N. Ionescu, Michael Cabanero, Charles Butts, Aly Karsan, Suzanne Kamel-Reid, Ming-Sound Tsao, M. Pakkal, Mahadeo A. Sukhai

    المصدر: Current Oncology
    Volume 24
    Issue 2
    Pages 3524-119

    مصطلحات موضوعية: Lung adenocarcinoma, 0301 basic medicine, Pathology, medicine.medical_specialty, EGFR, medicine.medical_treatment, Review Article, Targeted therapy, liquid biopsies, 03 medical and health sciences, T790M, 0302 clinical medicine, medicine, Lung cancer, resistant mutations, Practical implications, Lung, business.industry, re-biopsies, medicine.disease, respiratory tract diseases, Clinical trial, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Non small cell, business, Tyrosine kinase

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4bfa72724fecd9c435501c0b72ee05Test
    https://doi.org/10.3747/co.24.3524Test


    أضف إلى المفضلة
  5. 5
    Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)

    المؤلفون: Anna Zhou, S. Owen, Ahmed Abdulla, Federico Felizzi, Umang Ondhia, Noman Paracha, Julian Nam, Randeep Sangha, H J Conter, Sumeet Singh, Paula Chu

    مصطلحات موضوعية: Male, Oncology, Canada, medicine.medical_specialty, Lung Neoplasms, Cost effectiveness, Cost-Benefit Analysis, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Docetaxel, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Second line, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Neoplasm Invasiveness, neoplasms, health care economics and organizations, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, business.industry, 030503 health policy & services, Health Policy, Immunotherapy, Middle Aged, Prognosis, medicine.disease, Survival Analysis, respiratory tract diseases, Nivolumab, 030220 oncology & carcinogenesis, Female, Quality-Adjusted Life Years, 0305 other medical science, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec812c06c1dac777014f00e58cdf972Test


    أضف إلى المفضلة
  6. 6
    Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

    المؤلفون: Judith Raimbourg, Keunchil Park, Sjaak Burgers, Adam Pluzanski, Norbert Frickhofen, Ravi S. Kasinathan, Konstantinos N. Syrigos, Fabrice Barlesi, Enric Carcereny, Ang Li, Randeep Sangha, Reyes Bernabe Caro, Hossein Borghaei, Luis Paz-Ares, A. Vergnenegre, A. Alexandru, Mariano Provencio, L. Lupinacci

    المصدر: Cancer Research. 80:CT221-CT221

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, First line, Checkmate, Cancer, non-small cell lung cancer (NSCLC), Ipilimumab, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Nivolumab, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::fbe735c8621f1b9bb1860bd98bf380c9Test
    https://doi.org/10.1158/1538-7445.am2020-ct221Test


    أضف إلى المفضلة
  7. 7
    Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

    المؤلفون: Yeow Tee Goh, David MacDonald, Erik Vandendries, M. Luisa Paccagnella, Joseph Boni, Revathi Ananthakrishnan, Michinori Ogura, Nam H. Dang, Andrew Davies, Randeep Sangha

    المصدر: Journal of Drug Assessment

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, B-cell non-Hodgkin lymphoma, medicine.medical_treatment, Pharmacology, chemotherapy, Inotuzumab ozogamicin, 03 medical and health sciences, 0302 clinical medicine, rituximab, Internal medicine, hemic and lymphatic diseases, medicine, Dexamethasone, Cisplatin, Chemotherapy, business.industry, antibody-conjugate, Gemcitabine, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, B-Cell Non-Hodgkin Lymphoma, Rituximab, business, CD22+, medicine.drug, Research Article

    وصف الملف: text

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c897cff1e97d0b730ff398fc251c2f4Test
    https://eprints.soton.ac.uk/417872Test/


    أضف إلى المفضلة
  8. 8
    P2.17-28 Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC

    المؤلفون: Randeep Sangha, Charles Butts, Sunita Ghosh, D.C.C. Tsui

    المصدر: Journal of Thoracic Oncology. 13:S863

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Radiation therapy, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, Internal medicine, medicine.medical_treatment, medicine, Locally advanced, business, Real world data

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::70dd38e21d44ea16ace69538bc59a0fbTest
    https://doi.org/10.1016/j.jtho.2018.08.1554Test


    أضف إلى المفضلة
  9. 9
    Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

    المؤلفون: Natasha Perkins, Laurel A. Beckett, Primo N. Lara, Paul J. Hesketh, Tianhong Li, Philip C. Mack, Derick H Lau, David R. Gandara, Angela M. Davies, Randeep Sangha

    المصدر: Journal of Thoracic Oncology. 6(12):2112-2119

    مصطلحات موضوعية: Oncology, Adult, Diarrhea, Male, Mucositis, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Neutropenia, Combination therapy, medicine.medical_treatment, Kaplan-Meier Estimate, Docetaxel, Pharmacology, Article, Disease-Free Survival, Erlotinib Hydrochloride, Non-small cell lung cancer, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, neoplasms, Aged, Aged, 80 and over, Chemotherapy, business.industry, Middle Aged, medicine.disease, Pharmacodynamic separation, Phase II, Erlotinib, Pharmacodynamics, Quinazolines, Female, Taxoids, business, Febrile neutropenia, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91809eb90f738212eca55e49f77f760eTest


    أضف إلى المفضلة
  10. 10
    Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions

    المؤلفون: Alex A. Adjei, Everett E. Vokes, Hak Choy, Laurie E. Gaspar, Joan H. Schiller, Randeep Sangha, Primo N. Lara, Nagahiro Saijo, Paul Baas, David R. Gandara, Glenwood D. Goss

    المصدر: Clinical Lung Cancer. 10:322-330

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Limited Stage, Cancer Research, medicine.medical_specialty, Growth kinetics, business.industry, medicine.medical_treatment, medicine.disease, humanities, respiratory tract diseases, Clinical trial, Radiation therapy, Oncology, Immunology, medicine, Cooperative group, Non small cell, Intensive care medicine, Lung cancer, business, Etoposide, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e4520446b5bbbc3371cdded39153f83eTest
    https://doi.org/10.3816/clc.2009.n.044Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث